21-deoxycortisol has been researched along with Cancer of Prostate in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| du Toit, T; Gent, R; Swart, AC | 1 |
1 other study(ies) available for 21-deoxycortisol and Cancer of Prostate
| Article | Year |
|---|---|
11α-Hydroxyprogesterone, a potent 11β-hydroxysteroid dehydrogenase inhibitor, is metabolised by steroid-5α-reductase and cytochrome P450 17α-hydroxylase/17,20-lyase to produce C11α-derivatives of 21-deoxycortisol and 11-hydroxyandrostenedione in vitro.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 11-beta-Hydroxysteroid Dehydrogenase Type 2; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Aged; Androstenedione; Cell Line, Tumor; Cortodoxone; HEK293 Cells; Humans; Hydroxyprogesterones; Male; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2019 |